Physician profile
Peiling Chen
NPI 1477033751
$1,041.23
in general payments reported to CMS, 2019-2025
12 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.81 · 2022: $20.66 · 2023: $230 · 2024: $430 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $194.89 | 2023-2024 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $163.40 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $130.27 | 2024-2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $127.18 | 2023-2025 | Miebo, Vyzulta, Biotrue |
| Oyster Point Pharma, INC. | $90.73 | 2023-2024 | Tyrvaya |
| Dompe US, INC. | $85.22 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $77.40 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $51.69 | 2024 | |
| Abbvie INC. | $41.51 | 2023-2025 | Xen Glaucoma Treatment System |
| Novartis Pharmaceuticals Corporation | $34.37 | 2020-2023 | |
| Alcon Vision LLC | $30.00 | 2024 | Total30 |
| Oasis Medical, INC. | $14.57 | 2025 | Oasis Tears |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peiling Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.